Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.

Clinical and translational science - 1 May 2021

Jiang Xuemin, Wada Russ, Poland Bill, Kleijn Huub Jan, Fan Bin, Liu Guowen, Liu Hua, Kapsalis Stephanie, Yang Hua, Le Kha

Abstract excerpt

Ivosidenib is a once daily (q.d.), orally available, potent mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor approved for treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and intensive chemotherapy ineligible AML with a susceptible IDH1 mutation. Population pharmacokinetics (PKs; N = 253), exposure-response (efficacy [n = 201] and safety [n = 253]), and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Variation, Population

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 CYP3A Inhibitors

Share to Drug Interactions

Share to Long QT Syndrome

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 33493392
DOI: 10.1111/cts.12959
PMCID: PMC8212730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.PMID 33493392Read ↗

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.Semantic proximity Read ↗

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.Semantic proximity Read ↗

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.Semantic proximity Read ↗

Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia.Semantic proximity Read ↗

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.Semantic proximity Read ↗

Evaluating ivosidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.